MedTrace Logo

A Time-motion Study Comparing Self- to Nurse-vaccination With Influenza Vaccine

NCT01665807 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 868

Last updated 2017-04-19

Study results available
· View outcomes & findings →

Summary

The investigators hypothesize that people working in an acute care hospital setting will be able to successfully self-administer the intradermal vaccine (Intanza) in less time than nurse-administration of the regular intramuscular influenza vaccine (Vaxigrip). The investigators also hypothesize that people administering the intradermal vaccine for the second time will take less time to successfully administer than people administering it for the first time.

Conditions

Interventions

BIOLOGICAL

Intanza

Intanza influenza vaccine, trivalent split-virion, inactivated, approved for the 2012-2013 influenza season in northern hemisphere

BIOLOGICAL

Vaxigrip

Influenza vaccine, trivalent, split-virion, inactivated, approved for the 2012-2013 influenza season in the northern hemisphere

Sponsors & Collaborators

  • Sanofi Pasteur, a Sanofi Company

    collaborator INDUSTRY

  • Brenda Coleman

    lead OTHER

Principal Investigators

  • Brenda L Coleman, PhD · MOUNT SINAI HOSPITAL

  • Melissa Barton · MOUNT SINAI HOSPITAL

  • Christine Moore · MOUNT SINAI HOSPITAL

  • Shelly A McNeil, MD · Canadian Centre for Vaccinology

  • Joanne M Langley, MD · Canadian Centre for Vaccinology

  • Scott A Halperin, MD · Canadian Centre for Vaccinology

  • Allison J McGeer, MD, FRCPC · MOUNT SINAI HOSPITAL

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
69 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01665807 on ClinicalTrials.gov